- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.05. | BIO-WORKS TECHNOLOGIES AB: Bio-Works receives WorkBeads order worth SEK 2.5 million | 1 | Cision News | ||
| 15.05. | BIO-WORKS TECHNOLOGIES AB: Resolutions passed at Bio-Works Technologies' annual general meeting 2025 | 16 | Cision News | ||
| BIO-WORKS TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 15.05. | BIO-WORKS TECHNOLOGIES AB: Bio-Works reports first quarter 2025 | 1 | Cision News | ||
| 29.04. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives Order Worth SEK 2.4 Million from New European Customer in Vaccine Production | 1 | Cision News | ||
| 15.04. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 2 of 11 | 1 | Cision News | ||
| 14.04. | BIO-WORKS TECHNOLOGIES AB: Bio-Works receives SEK 12 million order from global pharmaceutical company - delivery scheduled for 2026 | 3 | Cision News | ||
| 01.04. | BIO-WORKS TECHNOLOGIES AB: Today is the first day of the second exercise period for Bio-Works Technologies AB's warrants of series TO 2 | 2 | Cision News | ||
| 27.03. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives New Orders for Custom GoBio Columns for the U.S. Gene Therapy Market | 2 | Cision News | ||
| 26.02. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives Order for WorkBeads Worth 2.65 Million SEK | 2 | Cision News | ||
| 21.02. | BIO-WORKS TECHNOLOGIES AB: Bio-Works publishes year-end report Q4 2024 | 1 | Cision News | ||
| 14.02. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies Doubles Production Capacity to Meet Growing Demand | 5 | Cision News | ||
| 10.02. | BIO-WORKS TECHNOLOGIES AB: Bio-Works receives a third follow-up order for WorkBeads affimAb worth SEK 4.0 million | 1 | Cision News | ||
| 31.01. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives Follow-Up Order for WorkBeads affimAb Worth 4.6 MSEK | 1 | Cision News | ||
| 14.01. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Confirms a New Order for WorkBeads affimAb for Use in Antibody Production for 11.2 MSEK | 1 | Cision News | ||
| 02.01. | BIO-WORKS TECHNOLOGIES AB: The first day to exercise Bio-Works Technologies AB's warrants of series TO 2 is today | 1 | Cision News | ||
| 07.08.24 | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.08.2024 | 1.007 | Xetra Newsboard | Das Instrument LY10 AU000000LLO8 LION ONE METALS CDIS EQUITY wird cum Kapitalmassnahme gehandelt am 07.08.2024 und ex Kapitalmassnahme am 08.08.2024 The instrument LY10 AU000000LLO8 LION ONE METALS... ► Artikel lesen | |
| 02.07.24 | Nasdaq Stockholm AB: Delisting of Bio-Works Technologies AB from Nasdaq First North Growth Market | 463 | GlobeNewswire | Bio-Works Technologies AB has applied for its shares to be delisted from Nasdaq
First North Growth Market.
Nasdaq Stockholm AB has approved the application and decided to delist the
shares in Bio-Works... ► Artikel lesen | |
| 27.06.24 | Nasdaq Stockholm AB: Bio-Works Technologies AB receives observation status | 307 | GlobeNewswire | On June 26, 2024, Bio-Works Technologies AB (the "Company") issued a press
release where the Company announced its intention to change listing from Nasdaq
First North Growth Market to Spotlight Stock... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PHATHOM PHARMACEUTICALS | 8,920 | +90,19 % | Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA (vonoprazan) Tablets through May 3, 2032 | FLORHAM PARK, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) today announced that the U.S. Food and Drug Administration (FDA) has approved Phathom's Citizen Petition... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 36,240 | +1,83 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
| QIAGEN | 40,060 | -0,55 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen von 47 auf 50 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Analyst Jan Koch zog in seinem am Dienstag... ► Artikel lesen | |
| ARCELLX | 68,10 | +2,81 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 14,370 | +6,37 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,485 | +20,02 % | Recursion Pharmaceuticals shares surge on AI model release | ||
| TARSUS PHARMACEUTICALS | 43,920 | -0,39 % | Oppenheimer assumes Tarsus stock at outperform on strong sales | ||
| BIONTECH | 95,35 | +0,05 % | Summit Therapeutics crasht - BioNTech in Sippenhaft | Wie gewonnen, so zerronnen: Die Aktie von Summit Therapeutics brach am vergangenen Freitag an der Nasdaq um rund 30 Prozent ein. Weitere Studiendaten zum großen Hoffnungsträger Ivonescimab, den die... ► Artikel lesen | |
| VERA THERAPEUTICS | 22,760 | -25,69 % | Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy | Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 46,880 | -3,99 % | ROUNDUP/Aktien New York: Knappes Plus - Gelassenheit trotz Zoll-Unruhen | NEW YORK (dpa-AFX) - Die US-Börsen haben am Dienstag knappe Kursgewinne erzielt. Die jüngst wieder aufflackernden, internationalen Handelsstreitigkeiten wegen der amerikanischen Zollpolitik scheinen... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 15,240 | +2,83 % | RBC Capital behält Outperform-Rating für Edgewise Therapeutics-Aktie bei | ||
| JANUX THERAPEUTICS | 26,210 | +5,86 % | Leerink cuts Janux Therapeutics price target to $89, keeps Outperform | ||
| EVOTEC | 7,060 | +0,94 % | Evotec, Mutares, Nvidia, Puma, Rheinmetall, The Platform Group - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| 89BIO | 10,250 | +3,12 % | 89bio, Inc.: 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization... ► Artikel lesen | |
| TREVI THERAPEUTICS | 7,060 | +4,75 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough | Haduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups (108 and 54 mg BID p
Patients saw a... ► Artikel lesen |
Das Unternehmen BIO-WORKS TECHNOLOGIES AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +5,40 % bei einem Aktienkurs von 0,147 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIO-WORKS TECHNOLOGIES AB finden Sie auf Wallstreet Online.